Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

The 2019 Worldwide Pharma & Biotech Industry R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2019.

 

Market Intelligence Research & Development

Tracon Bows Out Of Oncology For Lead Product As TAPPAS Is Stopped For Futility

Disappointment for the San Diego, CA-based firm as Phase III study of its lead product is deemed futile and it ends clinical research of the product in cancer.

Clinical Trials Cancer

Purple Patch For Pharma/Biotech R&D As NAS Launches Reach Record High

The pharma and biotech industries enjoyed their most productive year since the turn of the century in terms of number of novel products launched worldwide in 2018.

Launches Analysis

US FDA Filing Mistake For Fintepla Dents Zogenix

Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.

Drug Review Policy & Regulation

Bluebird Bio's Zynteglo Flies Through Its CHMP Review

A nod in record time from the European Medicines Agency’s CHMP for its beta-thalassemia gene therapy Zynteglo pushes bluebird bio out of the nest and into commercial territory.

Approvals Gene Therapy

Bluebird’s Gene Therapy LentiGlobin Coming Into Land In The EU?

Two charities say a positive CHMP opinion has been given to bluebird bio’s transfusion-dependent β-thalassemia gene therapy LentiGlobin at the first meeting of the EMA’s scientific committee at its new home in Amsterdam.

Approvals Blood & Coagulation Disorders
See All
Advertisement
UsernamePublicRestriction

Register